Retatrutide vs Tirzepatide: Which is More Effective?
Last updated: January 2026
Quick Answer
Phase 2 data shows retatrutide (24.2% weight loss) outperforms tirzepatide (20.9%). 58% of retatrutide patients lost ≥20% body weight versus 57% for tirzepatide at highest doses. Retatrutide adds a glucagon receptor component that enhances fat burning and metabolic rate.
Retatrutide vs Tirzepatide: Which is More Effective
Phase 2 data shows retatrutide (24.2% weight loss) outperforms tirzepatide (20.9%). 58% of retatrutide patients lost ≥20% body weight versus 57% for tirzepatide at highest doses. Retatrutide adds a glucagon receptor component that enhances fat burning and metabolic rate.
Choosing the right GLP-1 telehealth provider affects your treatment experience, costs, and outcomes. Key factors to compare include pricing transparency, medication options, provider credentials, support level, and insurance acceptance.
What to Look for in a Provider
- Licensed healthcare providers (physicians, NPs, or PAs) doing the prescribing
- Medications sourced from FDA-regulated or 503B compounding pharmacies
- Transparent pricing with no hidden enrollment or shipping fees
- Regular follow-up appointments included in the monthly cost
- Responsive customer support and easy prescription management
Our Top Recommendation
Remedy Meds is our top-rated provider with a 4.7/5 rating, offering $199-399/mo pricing with board-certified providers and free assessment. They serve patients across all 50 states with home medication delivery.
Related Questions
What is Retatrutide?
Retatrutide is Eli Lilly's next-generation weight loss drug in Phase 3 trials. It activates three receptors simultaneously (GLP-1, GIP, and glucagon), producing stronger weight loss than any currently approved medication. Phase 2 showed 24.2% average weight loss over 48 weeks.
When Will Retatrutide Be FDA Approved?
Eli Lilly launched the Phase 3 TRIUMPH program in 2024. FDA submission is expected in 2026, with potential approval in 2026-2027. Phase 3 results from the TRIUMPH-3 trial are expected in late 2025.